pan-PI3K/mTOR dual inhibitors ADC (Abbvie)

N/A

Report date: 2026/05/21 20:00:22

First In Class

Base Information

Drug Namepan-PI3K/mTOR dual inhibitors ADC (Abbvie)

Drug Alias Namepan-PI3K/mTOR dual inhibitors(Abbvie)

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)Biologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody

Mechanisms of ActionSerine/threonine-protein kinase mTOR inhibitorsPhosphatidylinositol 3 kinase alpha inhibitorsPhosphatidylinositol 3 kinase beta inhibitors +[5]

TargetsSerine/threonine-protein kinase mTORPhosphatidylinositol 3 kinase alphaPhosphatidylinositol 3 kinase beta +[5]

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesAbbvie Inc

China Registration ClassN/A

Develop Information

Active CompaniesAbbvie Inc

Inactive CompaniesN/A

Active IndicationsSolid tumours

Inactive IndicationsN/A

Other Information

ATC CodeN/A